Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans (NCT06485622) | Clinical Trial Compass
RecruitingNot Applicable
Outcome and Improvement of Different Treatment in Arteriosclerosis Obliterans
China400 participantsStarted 2024-07-01
Plain-language summary
This study is a prospective, single-center, observational study. In this study, we aim to evaluate the clinical outcome and cost-effectiveness of different treatments of lower extremity arterial occlusive disease. It is expected to include about 400 patients diagnosed with lower extremity arterial occlusive disease in our center from July 2024 to July 2026. All enrolled patients will be followed for three years. All patients diagnosed with arteriosclerosis obliterans (ASO) and all treatment techniques were included in this study. The primary outcomes include the Efficacy and Safety End Points of each techniques.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 18 years or older, gender is not limited.
✓. Patients diagnosed with arteriosclerosis obliterans.
✓. Rutherford stages 2-6.
✓. When there are multiple stenosis lesions, the treatment of the most severe lesion is included.
✓. Patients with at least one arterial occlusion ( iliac, femoral, popliteal, anterior tibial, posterior tibial, and/or peroneal artery) of the lower extremity were included.
Exclusion criteria
✕. Malignant tumor
✕. Alzheimer's disease
✕. Blood disease or bleeding tendency
✕. Heart Failure Grade III \~ IV
✕. Pregnancy or lactation
✕. An above-knee-below-knee amputation has been performed